Proteomic Analytics is Replacing Genomics as the New Frontier in Biotechnology - There is Plenty of Opportunity, and Some Completely New Types of Biomarkers are Already at Work
Proteomics is going mainstream. Where genomics couldn’t find all the answers proteomics is stepping up to the plate.
Who will be the Illumina of Proteomics? Will these new biomarkers redefine disease definitions? Will Proteomic Assays displace current Genomic Assays? Find out all about it and more in this comprehensive report.
Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life. Players are reporting double digit growth. Venture capital is well involved. Learn about this market including the issues and outlooks. This technology could possibly displace most cancer diagnostic protocols AND save money at the same time.
This research makes you the expert in your organization. All report data is available in Excel format on request. Assistance, and additional specific data, is provided without additional charges. Make investment decisions and valuations with confidence using the latest data.
The report forecasts the market size out for five years for a number of different market segments.
Table of Contents
Samples
LOADING...
Companies Mentioned
- Abbott Laboratories
- Agilent/Dako
- Amprion
- BasePair Biotechnologies
- Beckman Coulter Diagnostics
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne
- Bruker
- C2N Diagnostics
- Cepheid (Danaher)
- DeepMind
- Diadem Diagnostics
- Eve Technologies
- Exact Sciences
- Fluidic Analytics
- Fujirebio
- Hybrigenics Services
- Luminex Corp (DiaSorin)
- NanoDx
- NanoMosaic
- Nautilus Biotechnology
- Nicoya
- Octave Bioscience
- Olink
- PrognomiQ
- Qiagen
- Quanterix
- Roche Molecular Diagnostics
- Second Genome
- Siemens Healthineers
- Somalogic
- Thermo Fisher Scientific Inc.